Literature DB >> 1283683

Effects of muscarinic receptor agonists and antagonists on rat brain serotonergic activity.

S K Bhattacharya1, A P Sen.   

Abstract

The effects of some muscarinic M1 and M2 receptor agonists and antagonists on rat brain serotonergic activity was assessed by noting their effects on the levels of 5-hydroxytryptamine (5-HT) and its major metabolite, 5-hydroxyindole acetic acid (5-HIAA), estimated by a high pressure-liquid chromatographic (HPLC) technique. The muscarinic M1 receptor agonists, arecholine and McN-A-343, and the M2 receptor agonists, gallamine and AF-DX 116, induced a dose-related decrease in the concentrations of both 5-HT and 5-HIAA. On the contrary, scopolamine and the selective M1 receptor antagonist, pirenzepine, increased the levels of the amine and its metabolite. The anti-cholinesterase agent, physostigmine, and the putative M2 receptor agonist, carbachol, induced a dose-related dual effect, with the smaller doses decreasing and the higher doses increasing 5-HT and 5-HIAA concentrations. The results indicate that an inverse relationship exists between the cholinergic and serotonergic neurotransmitter systems in the rat brain due to the likely presence of muscarinic heteroreceptors on serotonergic neurones. The data also indicates that though physostigmine and carbachol may function as M2 receptor agonists, they lose their receptor specificity on dose increment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283683     DOI: 10.1007/bf01250965

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  23 in total

1.  Effect of selective muscarinic receptor agonists and antagonists on active-avoidance learning acquisition in rats.

Authors:  A P Sen; S K Bhattacharya
Journal:  Indian J Exp Biol       Date:  1991-02       Impact factor: 0.818

Review 2.  Muscarinic receptor subtypes in the central nervous system.

Authors:  W Hoss; J Ellis
Journal:  Int Rev Neurobiol       Date:  1985       Impact factor: 3.230

3.  Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.

Authors:  P T Francis; A M Palmer; N R Sims; D M Bowen; A N Davison; M M Esiri; D Neary; J S Snowden; G K Wilcock
Journal:  N Engl J Med       Date:  1985-07-04       Impact factor: 91.245

4.  Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides.

Authors:  T J Crow; A J Cross; S J Cooper; J F Deakin; I N Ferrier; J A Johnson; M H Joseph; F Owen; M Poulter; R Lofthouse
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

5.  Central muscarinic receptor subtypes and carrageenin-induced paw oedema in rats.

Authors:  S K Bhattacharya; A P Sen; G Das Gupta; K Seth; P K Seth
Journal:  Res Exp Med (Berl)       Date:  1991

6.  Selective impairment of acetylcholine release and content in the central nervous system following intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) in the rat.

Authors:  P E Potter; L G Harsing; I Kakucska; G Gaal; E S Vizi
Journal:  Neurochem Int       Date:  1986       Impact factor: 3.921

7.  Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain.

Authors:  M Raiteri; R Leardi; M Marchi
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

8.  On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties.

Authors:  M Marchi; M Raiteri
Journal:  J Pharmacol Exp Ther       Date:  1985-10       Impact factor: 4.030

9.  Effects of muscarinic receptor agonists and antagonists on response of non-extensor rats to maximal electroshock.

Authors:  S K Bhattacharya; A P Sen; S K Mitra
Journal:  Indian J Exp Biol       Date:  1991-03       Impact factor: 0.818

10.  Thermic response of selective muscarinic agonists and antagonists in rat.

Authors:  A P Sen; S K Bhattacharya
Journal:  Indian J Exp Biol       Date:  1991-02       Impact factor: 0.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.